Illumina shares plummeted by a quarter after it warned on Monday that its third-quarter sales were likely to come in below its own forecast and Wall Street’s due to a drop in revenue from a type of genetic sequencing instrument.

The diagnostic group said that it expects sales in the third quarter to have risen 10 per cent on a year-on-year basis to $607m, compared with an earlier estimate of $625m – $630m. That was also shy of analyst expectations of $628m.

Illumina said the shortfall in revenue came as a result of a bigger-than-expected year-on-year dip in sales of high-throughput sequencing instruments, or devices that can analyse a very high number of DNA molecules at the same time.

Shares of the California-based company fell as much as 26 per cent in after hours trading. They were down by 3.7 per cent for 2016 as of Monday’s close.

Copyright The Financial Times Limited 2019. All rights reserved.

Comments have not been enabled for this article.

Follow the topics in this article